Bafna Pharmaceuticals (BAFNAPH) Q1 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter ended June 30, 2024, were approved and reviewed by the Board and Audit Committee on August 13, 2024.

• The 29th Annual General Meeting is scheduled for September 25, 2024, via video conferencing.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹3,328 lakhs, down from ₹4,139 lakhs in Q4 FY24 and ₹4,194.71 lakhs in Q1 FY24.

• Total income for the quarter was ₹3,379.16 lakhs, compared to ₹4,191.34 lakhs in the previous quarter and ₹4,381.62 lakhs year-over-year.

• Net loss for Q1 FY25 was ₹72.36 lakhs, compared to a net profit of ₹145.54 lakhs in Q4 FY24 and ₹635.11 lakhs in Q1 FY24.

• Earnings per share (basic and diluted) for the quarter were ₹(0.31), compared to ₹0.62 in Q4 FY24 and ₹2.68 in Q1 FY24.

• Exceptional item of ₹34.50 lakhs in Q1 FY25 due to derecognition of certain inventory items.

Key financial ratios and metrics

• Gross margin and other detailed ratios not explicitly provided, but significant decline in profitability and revenue year-over-year.